Piper Jaffray Companies Analysts Give Bausch Health Companies (NYSE:BHC) a $29.00 Price Target
Piper Jaffray Companies set a $29.00 price objective on Bausch Health Companies (NYSE:BHC) in a research note released on Tuesday morning, TipRanks reports. The brokerage currently has a buy rating on the stock.
Other equities analysts also recently issued reports about the company. ValuEngine raised Bausch Health Companies from a sell rating to a hold rating in a research report on Wednesday, May 8th. Zacks Investment Research raised Bausch Health Companies from a hold rating to a buy rating and set a $27.00 price target on the stock in a research report on Tuesday, May 21st. Cantor Fitzgerald set a $32.00 price target on Bausch Health Companies and gave the stock a buy rating in a research report on Friday, May 31st. Barclays began coverage on Bausch Health Companies in a research report on Tuesday. They set an overweight rating and a $28.00 price target on the stock. Finally, Wells Fargo & Co set a $9.00 price target on Bausch Health Companies and gave the stock a sell rating in a research report on Friday, May 17th. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and ten have given a buy rating to the stock. Bausch Health Companies currently has an average rating of Hold and a consensus target price of $27.65.
Shares of BHC stock opened at $22.13 on Tuesday. The firm has a market cap of $7.63 billion, a PE ratio of 5.50, a price-to-earnings-growth ratio of 0.48 and a beta of 0.61. The company has a debt-to-equity ratio of 8.61, a quick ratio of 0.83 and a current ratio of 1.08. Bausch Health Companies has a 12-month low of $17.20 and a 12-month high of $28.45.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Orbimed Advisors LLC boosted its holdings in Bausch Health Companies by 89.1% in the fourth quarter. Orbimed Advisors LLC now owns 3,600,300 shares of the company’s stock valued at $66,498,000 after purchasing an additional 1,696,400 shares during the last quarter. Financial Sense Advisors Inc. boosted its holdings in Bausch Health Companies by 7.7% in the fourth quarter. Financial Sense Advisors Inc. now owns 84,250 shares of the company’s stock valued at $1,556,000 after purchasing an additional 6,050 shares during the last quarter. Bank of Nova Scotia boosted its holdings in Bausch Health Companies by 14.6% in the fourth quarter. Bank of Nova Scotia now owns 1,207,147 shares of the company’s stock valued at $22,296,000 after purchasing an additional 154,143 shares during the last quarter. Bessemer Group Inc. purchased a new stake in shares of Bausch Health Companies during the 4th quarter worth about $33,000. Finally, Highstreet Asset Management Inc. purchased a new stake in shares of Bausch Health Companies during the 1st quarter worth about $354,000. 53.67% of the stock is currently owned by hedge funds and other institutional investors.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Further Reading: Trading Strategy Methods and Types
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.